While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...
Walgreens jumps as Sycamore agrees to $11.45 a share purchase Sycamore Partners agreed to acquire Walgreens Boots (WBA) in a ...
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
The makers of two popular weight-loss drugs—Wegovy and Zepbound—are cutting prices to make the medications more affordable for people without insurance. Novo Nordisk, the Danish company behind Wegovy, ...
A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...
The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more af ...
Zacks Investment Research on MSN2d
Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & MoreBayer BAYRY announced its fourth-quarter and full-year 2024 results. AbbVie ABBV announced a licensing deal with Danish firm ...
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
According to Halozyme, the new version of Keytruda infringes on its patents, the report said. USAID cuts put tuberculosis response in peril, WHO says The Trump administration's decision to pause U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback